- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06716073
Langzeitergebnisse endoskopisch unterstützter vs. konventioneller brusterhaltender Chirurgie bei Brustkrebspatientinnen nach neoadjuvanter Therapie: eine randomisierte, multizentrische, offene Nicht-Minderwertigkeitsstudie
With the title of "Long-Term Outcomes of endoscopic-assisted vs conventional breast-conserving surgery in breast cancer patients after neoadjuvant therapy: a randomized, multicenter, open label, non-inferiority trial", this study targets breast cancer patients after neoadjuvant therapy. A total of 804 eligible patients, after screening with inclusion and exclusion criteria, will be randomly assigned to Endoscopic-assisted breast conserving surgery(E-BCS) or conventional breast conserving surgery (C-BCS) group at a 1:1 ratio using stratified block randomization method, stratified by centers and molecular subtype. The co-primary endpoints are 5-year disease-free survival (5y-DFS) and Breast-Q score at 6 months after surgery. The secondary endpoints are cosmetic outcomes including surgeons' satisfaction with breast and patients' satisfaction with scar, survival outcomes including 5-year overall survival (5y-OS) and 5-year local-recurrence rate (5y-LRR), surgical outcomes including operative time, intraoperative blood loss, incision length and postoperative complications rate. This study aims to confirm the long-term safety and aesthetic outcome of endoscopic-assisted surgery in breast cancer patients after neoadjuvant treatment by comparing it with conventional open breast conserving surgery, and provide clinical evidence for the popularized application of endoscopic breast surgery.
Studienübersicht
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Shicheng Su
- Telefonnummer: +86-13631304227
- E-Mail: sushch@mail.sysu.edu.cn
Studieren Sie die Kontaktsicherung
- Name: Yiwen Lu, Doctor
- Telefonnummer: +86-13268121885
- E-Mail: luyw8@mail.sysu.edu.cn
Studienorte
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Rekrutierung
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
Kontakt:
- Shicheng Su
- Telefonnummer: +86-13631304227
- E-Mail: sushch@mail.sysu.edu.cn
-
Shantou, Guangdong, China
- Noch keine Rekrutierung
- Sun Yat-sen Memorial Hospital of Sun Yat-sen University Shenzhen Shantou Central Hospital
-
Kontakt:
- Yandan Yao
- Telefonnummer: +86-13826292688
- E-Mail: yaoyand@mail.sysu.edu.cn
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age ranging from 18 to 75 years
- Pathologically confirmed invasive breast cancer
- Receiving preoperative chemotherapy (Each molecular subtype corresponds to unanimous regimen)
- cT1-3N0-3M0
- Unilateral breast tumor
- Eastern Cooperative Oncology Group score 0-1
- Left Ventricular Ejection Fraction (LVEF) ≥50%
- Leukocytes ≥ 3.0×109/L, Absolute neutrophil count ≥ 1.5×109/L, Platelets ≥ 100×109/L, Hemoglobin ≥ 90g/L, Creatinine <1.5 × institutional ULN, Total bilirubin ≤ 2.0 × institutional ULN.
Exclusion Criteria:
- Diffusely disseminated malignant calcification foci
- Not applicable for BCS after neoadjuvant therapy
- Pregnancy or breastfeeding
- Additional malignancy
- Severe cardiopulmonary, liver or kidney dysfunction or other systemic diseases (such as uncontrolled chronic heart failure, critical hypertension or diabetes with poor blood glucose control).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Gruppe für endoskopische brusterhaltende Chirurgie (E-BCS).
|
comparison of 2 surgical procedures |
|
Kein Eingriff: Gruppe der konventionellen brusterhaltenden Chirurgie (C-BCS).
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
5-year disease free survival
Zeitfenster: From surgery to the end of follow-up at 5 years
|
The proportion of patients remaining after excluding patients with disease recurrence, metastasis or death from the time of surgery to 5-year follow-up |
From surgery to the end of follow-up at 5 years
|
|
Patients' satisfaction with breast
Zeitfenster: From surgery to the follow-up at 6 months
|
The score of Breast-Q scale "Satisfaction with breasts" table 6 months after surgery |
From surgery to the follow-up at 6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Surgeons' satisfaction with breast
Zeitfenster: From surgery to the follow-up at 6 months
|
Surgeons evaluate the cosmetic outcome of breast based on the photos before surgery and after surgery. Four ranks: Excellent (9-10 points), Good (7-8 points), Fair (5-6 points) and Poor (0-4 points) are categorized on a basis of average total score from Ueda scale |
From surgery to the follow-up at 6 months
|
|
Patients satisfaction with scar
Zeitfenster: From surgery to the follow-up at 6 months
|
Scar-Q scale including 3 tables about the surgical scar: appearance, symptom, psychosocial impact with total score of 100 will be used for evaluating patients satisfaction with scar |
From surgery to the follow-up at 6 months
|
|
5-year overall survival
Zeitfenster: From surgery to the end of follow-up at 5 years
|
The proportion of patients remaining after excluding patients who died from any cause at 5-year follow-up |
From surgery to the end of follow-up at 5 years
|
|
5-year local-regional recurrence rate
Zeitfenster: From surgery to the end of follow-up at 5 years
|
The proportion of patients with a lump found on breast, axilla, chest wall, skin or scars of surgery ipsilateral to the surgical side through physical examination or imaging, confirmed as the same pathological type as the primary tumor according to biopsy at 5-year follow up |
From surgery to the end of follow-up at 5 years
|
|
Postoperative complication rate
Zeitfenster: From surgery to the follow-up at 12 months
|
The proportion of patients with postoperative complications including hemorrhage, incision dehiscence, upper limb lymphedema, infection,seroma. |
From surgery to the follow-up at 12 months
|
|
Surgical duration
Zeitfenster: Intraoperative
|
The time from the beginning of surgery to the end of surgery |
Intraoperative
|
|
Intraoperative blood loss
Zeitfenster: Intraoperative
|
The blood loss during the operation |
Intraoperative
|
|
Incision length
Zeitfenster: Intraoperative
|
The length of surgical incision |
Intraoperative
|
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: Shicheng Su, Doctor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- SYSKY-2024-648-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .